5 Hrs
Source:
Forbes
_1777370220974_847775619.png&w=64&q=75){kind=small}
Gilgamesh Challenges Big Pharma's Psychedelic Reach
A biotech startup sold a psychedelic compound to AbbVie for $1.2 billion last year. Its founders are now developing additional compounds aimed at treating depression and other mental health conditions.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)